Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs

被引:34
|
作者
Hoj, Stine Bordier [1 ]
Jacka, Brendan [1 ]
Minoyan, Nanor [1 ,2 ]
Artenie, Andreea Adelina [1 ,2 ]
Bruneau, Julie [1 ,3 ]
机构
[1] CRCHUM, 900 Rue St Denis,Local R05-746, Montreal, PQ H2X 0A9, Canada
[2] Univ Montreal, Ecole Sante Publ, 7101 Ave Parc, Montreal, PQ H3N 1X9, Canada
[3] Univ Montreal, Fac Med, Dept Med Familiale & Med Urgence, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada
基金
加拿大健康研究院;
关键词
Hepatitis C virus; Treatment; Health services; Injection drug use; Theoretical framework; Ecological framework; HEPATITIS-C VIRUS; PATIENT-REPORTED OUTCOMES; LONG-TERM CONDITIONS; HEALTH-CARE; HIV CARE; UNDERSTANDING BARRIERS; TREATMENT CANDIDACY; BEHAVIORAL-MODEL; UNITED-STATES; SPECIALIST ASSESSMENT;
D O I
10.1016/j.drugpo.2019.04.001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
As direct-acting antiviral (DAA) therapy costs fall and eligibility criteria are relaxed, people who inject drugs (PWID) will increasingly become eligible for HCV treatment. Yet eligibility does not necessarily equate to access. Amidst efforts to expand treatment uptake in this population, we seek to synthesise and clarify the conceptual underpinnings of access to health care for PWID, with a view to informing research and practice. Integrating dominant frameworks of health service utilisation, care seeking processes, and ecological perspectives on health promotion, we present a comprehensive theoretical framework to understand, investigate and intervene upon barriers and facilitators to HCV care for PWID. Built upon the concept of Candidacy, the framework describes access to care as a continually negotiated product of the alignment between individuals, health professionals, and health systems. Individuals must identify themselves as candidates for services and then work to stake this claim; health professionals serve as gatekeepers, adjudicating asserted candidacies within the context of localised operating conditions; and repeated interactions build experiential knowledge and patient-practitioner relationships, influencing identification and assertion of candidacy over time. These processes occur within a complex social ecology of interdependent individual, service, system, and policy factors, on which other established theories provide guidance. There is a pressing need for a deliberate and nuanced theory of health care access to complement efforts to document the HCV 'cascade of care' among PWID. We offer this framework as an organising device for observational research, intervention, and implementation science to expand access to HCV care in this vulnerable population. Using practical examples from the HCV literature, we demonstrate its utility for specifying research questions and intervention targets across multiple levels of influence; describing and testing plausible effect mechanisms; and identifying potential threats to validity or barrierS to research translation.
引用
收藏
页码:11 / 23
页数:13
相关论文
共 50 条
  • [31] Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses
    Lazarus, J. V.
    Safreed-Harmon, K.
    Stumo, S. R.
    Jauffret-Roustide, M.
    Maticic, M.
    Reic, T.
    Schatz, E.
    Tallada, J.
    Harris, M.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 47 : 47 - 50
  • [32] "It's not Simple and It's Not Straight Forward": Challenges and Opportunities in Scaling up Access of Direct-Acting Antiviral Hepatitis C Virus Treatment to People Who Inject Drugs
    Goodyear, Trevor
    Ti, Lianping
    Small, Will
    Knight, Rod
    INTERNATIONAL JOURNAL OF QUALITATIVE METHODS, 2020, 19
  • [33] Strategies of hepatitis C virus elimination for people who inject drugs receiving opioid agonist therapy in the era of direct-acting antivirals
    Sou, Fai-Meng
    Chen, Chien-Hung
    Huang, Pao-Yuan
    Tsai, Ming-Chao
    Yen, Yi-Hao
    Lu, Sheng-Nan
    Hung, Chao-Hung
    Kuo, Yuan-Hung
    ADVANCES IN DIGESTIVE MEDICINE, 2024, 11 (04) : 189 - 195
  • [34] Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy
    Wong, Grace Lai-Hung
    Chan, Henry Lik-Yuen
    Loo, Ching-Kong
    Hui, Yee-Tak
    Fung, James Yue-Yan
    Cheung, David
    Chung, Cedric
    Chim, Angel Mei-Ling
    Wong, Vincent Wai-Sun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (09) : 1641 - 1647
  • [35] Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens
    Akiyama, Matthew J.
    Riback, Lindsey
    Reeves, Jacqueline D.
    Lie, Yolanda S.
    Agyemang, Linda
    Norton, Brianna L.
    Arnsten, Julia H.
    Litwin, Alain H.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (10):
  • [36] Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study
    Lopes, Snehal S.
    Pericot-Valverde, Irene
    Lum, Paula J.
    Taylor, Lynn E.
    Mehta, Shruti H.
    Tsui, Judith I.
    Feinberg, Judith
    Kim, Arthur Y.
    Norton, Brianna L.
    Page, Kimberly
    Murray-Krezan, Cristina
    Anderson, Jessica
    Karasz, Alison
    Arnsten, Julia
    Moschella, Phillip
    Heo, Moonseong
    Litwin, Alain H.
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [37] Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
    Cheng, Qinglu
    Cunningham, Evan B.
    Shih, Sophy
    Amin, Janaki
    Bruneau, Julie
    Artenie, Adelina A.
    Powis, Jeff
    Litwin, Alain H.
    Cooper, Curtis
    Dalgard, Olav
    Hellard, Margaret
    Bruggmann, Philip
    Marks, Philippa
    Lacombe, Karine
    Stedman, Catherine
    Read, Phillip
    Hajarizadeh, Behzad
    Dunlop, Adrian J.
    Conway, Brian
    Feld, Jordan J.
    Dore, Gregory J.
    Grebely, Jason
    VALUE IN HEALTH, 2023, 26 (06) : 883 - 892
  • [38] How can general practitioners support people who inject drugs to engage with direct-acting antiviral treatment for hepatitis C? A qualitative study
    Heard, Emma
    Smirnov, Andrew
    Massi, Luciana
    Selvey, Linda A.
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2021, 50 (10) : 716 - 721
  • [39] Systematic review and meta-analysis of sustained viral response to hepatitis C direct-acting antiviral therapy in people who currently inject drugs
    Latham, N.
    Doyle, J.
    Agius, P.
    Vanhommerig, J.
    Palmer, A.
    Pedrana, A.
    Goutzamanis, S.
    Aspinall, E.
    Hutchinson, S.
    Hellard, M.
    Sacks-Davis, R.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 59 - 60
  • [40] "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs
    Goodyear, Trevor
    Ti, Lianping
    Carrieri, Patrizia
    Small, Will
    Knight, Rod
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 81